Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders,
4th Annual Gene Therapy Patient Engagement Summit
Join Sonia VALERO, Head of Clinical Operations and Patient Advocacy Representative at Vivet Therapeutics’ at the 4th Annual Gene Therapy Patient Engagement Summit in Boston, 29-31 May!
5th Annual Gene Therapy Analytical Development Europe Summit
Join us in London next week at the 5th Annual Gene Therapy Analytical Development Europe Summit, 22-24 May, where our Chief Operating Officer, @Anne Douar will be participating in a panel discussion
Genome Regulation and Cellular Fates in Homeostasis and Disease conference
📢 Listen in as @Vivet Therapeutics Co-founder and Chief Scientific Officer, @Gloria Gonzalez-Aseguinolaza participates in a round table discussion at the Genome Regulation and Cellular Fates in Homeostasis and Disease conference in Madrid from 13 – 14 May.
BioEquity Europe 2024, from 12 – 14 May in San Sebastian, Spain!
Don’t miss the opportunity to connect with our CEO @Jean-Philippe Combal & General Counsel & Head of Finance @Susan Coles at #BioEquity Europe 2024, from 12 – 14 May in San Sebastian, Spain!
We are presenting at the 27th Annual @American Society of Gene & Cell Therapy (#ASGCT)
Save the date! We are presenting at the 27th Annual @American Society of Gene & Cell Therapy (#ASGCT) Meeting next week in Baltimore, MD! 📌 Abstract Title: S/MAR-Containing AAV Vectors Result in an Increase in AVV Episomes & a Reduction in AAV Integration Sites in a Mouse Model with a High Rate of Hepatocyte Proliferation
Our CEO Jean-Philippe Combal will join a panel of key industry leaders at the 10th Annual LSX World Congress
We’re thrilled to share that our CEO Jean-Philippe Combal will join a panel of key industry leaders at the 10th Annual LSX World Congress to provide insight on best practices, strategies and real-life experiences that drive innovation in cell and gene therapy (#CGT).
Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024
Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is pleased to announce that its management team will be participating and presenting at the following scientific and business conferences in April, May and June in 2024.
Round table discussion on ‘Therapeutic Advances’ on the ‘Current Situation of Rare Diseases in Spain’.
Vivet Therapeutics Co-founder and Chief Scientific Officer, Gloria Gonzalez-Aseguinolaza will be participating in a round table discussion on ‘Therapeutic Advances’ on the ‘Current Situation of Rare Diseases in Spain’.
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease